Molecular Analysis of Acute Myeloid Leukemia

Simple SummaryContent extracted from patent full text and abstract with AI.

The patent discloses a method and associated diagnostic tools for detecting Acute Myeloid Leukemia (AML) by analyzing the abundance of specific RNA molecules in a patient’s blood sample. By measuring at least 4 (and preferably more) predetermined RNAs from a defined gene set, the method employs classification algorithms to reliably distinguish AML patients from healthy individuals. The invention also includes microarrays, kits, and algorithms for use in non-specialist clinical settings, enabling earlier and more accurate AML diagnoses without needing invasive bone marrow procedures or specialist interpretation.

Use CasesContent extracted from patent full text and abstract with AI.

• Early and accurate primary diagnosis of AML from blood samples in general practice or primary care settings.
• High-throughput population screening for AML using blood-based RNA signatures.
• Development of diagnostic kits or microarrays for laboratories to perform standardized AML detection.
• Clinical decision support for rapid referral and treatment planning for AML patients.
• Research use in distinguishing AML from other hematological or infectious diseases using molecular profiles.

BenefitsContent extracted from patent full text and abstract with AI.

• Non-invasive diagnosis: Only a blood sample is needed, avoiding bone marrow biopsy.
• High sensitivity and specificity (>99%): Enables highly reliable diagnosis of AML.
• Rapid turn-around: Suitable for use in non-specialist settings, allowing earlier therapy initiation.
• Scalable and cost-effective: Can utilize microarray or PCR-based platforms that process many samples at once.
• Reduces misdiagnosis: Improves distinction between AML and similar presenting infections or conditions.
• Facilitates decentralized testing: Private practitioners can diagnose or triage AML without requiring immediate specialist referral.
• Enables adaptive and robust classification: Utilizes advanced algorithms validated on large, multi-center datasets.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides a method for molecular analysis of Acute Myeloid Leukemia (AML)based on the abundance of particular RNAs from blood samples, as well as diagnostic tools such as kits and arrays suitable for such method.